Strides Pharma Consolidates European Business-to-Business Operations in Switzerland
- Market proximity of Strides Pharma International AG, based in Zug, Switzerland, opens the way for rapid technology transfer and innovation within the European market
- Oren Weininger, longstanding leader at Fairmed Healthcare, heads the business as CEO and Chairman of the Board
Zug, Switzerland. Strides Pharma Science Limited, globally recognized as a leading pharmaceutical company operating across 100 countries and headquartered in Bangalore, India, is consolidating its European business through Strides Pharma International AG, based in Zug, Switzerland.
Strides Pharma specializes in the development and manufacturing of IP-led niche finished dosage formulations. With over three decades of research and development expertise, Strides Pharma continuously develops and delivers products with innovative and improved technologies at competitive prices. Notably, Strides Pharma is among the world's largest manufacturers of Ibuprofen and Macrogol in various forms. Their unique range of drug delivery technologies opens up versatile and lucrative opportunities within the ever-evolving target markets.
The partner-centric in-licensing portfolio of over 250 formulations is consolidated in synergICE as a one-stop shop. It includes generics, sterile injectables and value-added products, Women´s Health hormones, lyophilized orally dissolving tablets and end-to-end biopharmaceutical CDMO services.
Oren Weininger, newly appointed Chairman of the Board, stated, “With this strengthened European B2B presence, we can respond faster to our customers’ needs and provide flexible, innovative solutions, and interesting generic portfolio, including comprehensive support in supply chain & quality management and regulatory processes by Strides Pharma International and the EU GMP-site in Hamburg, Germany.”
Key Markets are Central and Southern Europe (especially Germany), Scandinavia, Benelux and the Visegrád countries.
For further information, please visit: www.fair-med.com/newsroom
Contact Agency What About Now, Andreas Schöpf
as@whataboutnow.de Tel. +49 160 90723690
Following his roles at Dexcel Pharma and Kamedis, Oren Weininger took the position of CEO at Fairmed Healthcare AG in 2014 and subsequently became owner in 2018. Strides Pharma, after a period of successful partnership, invested in the company in 2019, further bolstering leading Fairmed Healthcare product lines. In addition to being appointed Chairman of the Board of Strides Pharma International AG, Weininger continues to lead Fairmed Healthcare GmbH in Hamburg.
Strides Pharma Science Limited, headquartered in Bangalore, India, was incorporated in 1990. The company has a global manufacturing footprint with eight facilities spread across four continents and a strong presence in 100 countries. Strides Pharma is a key active pharmaceutical ingredient manufacturer and producer of various products; every fourth Ibuprofen tablet on the global market today is supplied by Strides Pharma.
Images
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Japan’s CBD Industry Recieves First Investments From Publicly Listed Companies Following13.12.2024 09:36:45 CET | Pressmeddelande
AstraSana Japan Co., Ltd. has formed a capital and business alliance with Japan’s GSI Creos Corporation, bolstered by their investment. This partnership will enhance the wholesale distribution of CBD raw materials across Japan, leveraging the strengths of both companies. Through this alliance, the AstraSana Group, headquartered in Switzerland, will establish a robust supply chain to deliver Swiss-made, high-quality CBD raw materials across Japan, with a mission is to ensure customers receive safe, reliable products of the highest standard. Through this alliance, AstraSana Group (headquartered in Switzerland) will establish a stable supply chain to deliver Swiss-made, high-quality CBD raw materials nationwide in Japan. We aim to provide safe and reliable products to our customers. By leveraging GSI Creos’ extensive resources and networks, AstraSana says it will offer even higher-quality services to customers. Based on this robust partnership, it will actively contribute to the growth an
Innovation competition of the German government for digital identity wallets enters final round with Lissi GmbH12.12.2024 09:43:15 CET | Pressmeddelande
Berlin, 11.12.2024 - Lissi GmbH has qualified for the final phase of the EUDI-Wallet prototype competition organised by the German Federal Agency for Leap Innovation (SPRIND). The competition promotes innovative solutions for the implementation of the European eIDAS 2.0 regulation.
FEV and ProLogium develop high-performance vehicle battery5.12.2024 15:37:24 CET | Press Release
Aachen – Customer requirements for the evolution of electric cars are clearly defined: reduced weight at increased efficiency, higher range at shorter charging times and maximum safety. FEV, Germany's innovation powerhouse for the automotive and energy industry, and ProLogium, global pioneer in developing advanced vehicle batteries, fulfill precisely these requirements with their new product.
VYTAL Global enters the U.S. market with the launch of VYTAL US Inc.5.12.2024 09:00:52 CET | Press Release
VYTAL Global acquires certain assets and team members from TURN to drive tech-enabled reuse solutions
ELATEC Group Expands Leadership Team with Security Innovation Expert Jason Ouellette3.12.2024 13:56:22 CET | Press Release
Munich, December 3, 2024 – ELATEC Group welcomes Jason Ouellette as Corporate Vice President of Innovation & Technical Partnerships. With 30 years of experience in the physical security industry, Ouellette brings a wealth of expertise that will drive ELATEC’s technological advancements and strategic growth.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom